According to ChinaNews, with the outbreak of the H7N9 avian influenza, China’s State Food and Drug Administration of Drug Evaluation Center has approved the new drug “peramivir” developed in China into the market.
Since the SARS outbreak in 2003, under the unified arrangements of the Ministry of Science and Technology, Health and Family Planning Commission, the General Logistics Department of the Ministry of Health’s, after 10 years of research, a team led by the Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences researcher Li Song has successfully developed diosmin phosphate oseltamivir capsules, granules and peramivir trihydrate and a series of other anti-flu drugs, some had won the national invention patent and global intellectual property.
With the outbreak of the H7N9 avian influenza, Li Song together with a team performed the H7N9 virus genome sequence analysis, found out that structure of H7N9 virus neuraminidase is stable and N9 homology is greater than 98% suggesting that neuraminidase inhibitors will be effective for the epidemic. Peramivir is a new potent neuraminidase inhibitor which is effective on influenzae type HXNX virus including the recent H7N9 avian influenza.
Li Song said that the research and development of peramivir injection lasted for eight years, and all clinical studies had been completeed in 2011. It passed the technical review of the drug trial centers in December 2012. With the final approval obtained, this H7N9 avian influenza drug is expected to be available in the market soon.
Reference Link: http://www.chinanews.com/jk/2013/04-06/4705205.shtml